Physician profile
Michael Mullane
NPI 1386665081
$963.59
in general payments reported to CMS, 2019-2025
17 companies · $99.39 in 2025
The $99.39 reported for 2025 was less than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $172 · 2021: $138 · 2022: $235 · 2023: $134 · 2024: $185 · 2025: $99.39.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $419.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $418.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novocure Gmbh | $200.00 | 2022 | |
| Genentech USA, INC. | $139.01 | 2019-2023 | Tecentriq, Phesgo, Kadcyla |
| Glaxosmithkline, LLC. | $129.00 | 2021-2025 | Jemperli, Zejula |
| Comsort, INC | $100.00 | 2019 | |
| Astellas Pharma US INC | $65.67 | 2021-2024 | Padcev |
| Gilead Sciences, INC. | $59.40 | 2024-2025 | Trodelvy |
| Astrazeneca Pharmaceuticals Lp | $41.03 | 2023-2024 | Lynparza |
| Merck Sharp & Dohme LLC | $40.68 | 2021-2025 | Keytruda, Keytruda Qlex |
| Daiichi Sankyo INC. | $26.21 | 2024 | Enhertu |
| Mirati Therapeutics, INC. | $25.93 | 2024 | Krazati |
| Lilly USA, LLC | $25.56 | 2023 | Verzenio, Jaypirca |
| E.R. Squibb & Sons, L.L.C. | $23.85 | 2019 | |
| Emd Serono, INC. | $21.01 | 2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $17.96 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $17.39 | 2025 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $16.26 | 2024 | |
| Pfizer INC. | $14.63 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Mullane listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.